Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://amieaidg165668.wikigdia.com/8153507/novo_nordisk_s_retatrutide_australia_a_promising_breakthrough_for_losing_weight